191 related articles for article (PubMed ID: 1379060)
1. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Malave JJ
Br J Cancer; 1992 Jul; 66(1):198-203. PubMed ID: 1379060
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms by which cancer chemotherapeutic drugs induce emesis.
Cubeddu LX
Semin Oncol; 1992 Dec; 19(6 Suppl 15):2-13. PubMed ID: 1485177
[TBL] [Abstract][Full Text] [Related]
3. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies.
Cubeddu LX; O'Connor DT; Hoffmann I; Parmer RJ
Br J Cancer; 1995 Oct; 72(4):1033-8. PubMed ID: 7547218
[TBL] [Abstract][Full Text] [Related]
4. The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens.
du Bois A; Vach W; Siebert C; Holy R; Ledergerber M; Wechsel U; Kriesinger-Schroeder H
Support Care Cancer; 1997 May; 5(3):212-8. PubMed ID: 9176967
[TBL] [Abstract][Full Text] [Related]
5. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics.
Cubeddu LX; Hoffmann IS
J Clin Pharmacol; 1993 Aug; 33(8):691-7. PubMed ID: 7691898
[TBL] [Abstract][Full Text] [Related]
6. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
Castejon AM; Paez X; Hernandez L; Cubeddu LX
J Pharmacol Exp Ther; 1999 Dec; 291(3):960-6. PubMed ID: 10565811
[TBL] [Abstract][Full Text] [Related]
7. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients.
Cubeddu LX
Oncology; 1996 Jun; 53 Suppl 1():18-25. PubMed ID: 8692546
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic investigation of 5-day multiple dose of tropisetron capsule in patients who had received cisplatin and the usefulness of tropisetron capsule in the treatment of nausea and vomiting].
Suminaga M; Akasaka Y; Nukariya N; Kimura A; Ohtawa M
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1209-21. PubMed ID: 7544965
[TBL] [Abstract][Full Text] [Related]
9. Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy.
Janes RJ; Muhonen T; Karjalainen UP; Wiklund T
Eur J Cancer; 1998 Jan; 34(1):196-8. PubMed ID: 9624258
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
[TBL] [Abstract][Full Text] [Related]
11. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients.
Alfieri AB; Cubeddu LX
Br J Cancer; 1995 Mar; 71(3):629-32. PubMed ID: 7533519
[TBL] [Abstract][Full Text] [Related]
12. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Higa GM; Auber ML; Altaha R; Piktel D; Kurian S; Hobbs G; Landreth K
J Oncol Pharm Pract; 2006 Dec; 12(4):201-9. PubMed ID: 17156592
[TBL] [Abstract][Full Text] [Related]
13. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy.
Cubeddu LX; O'Connor DT; Parmer RJ
J Clin Oncol; 1995 Mar; 13(3):681-7. PubMed ID: 7533826
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
16. The role of serotonin as a mediator of emesis induced by different stimuli.
du Bois A; Kriesinger-Schroeder H; Meerpohl HG
Support Care Cancer; 1995 Sep; 3(5):285-90. PubMed ID: 8520873
[TBL] [Abstract][Full Text] [Related]
17. Urinary serotonin metabolite excretion during cisplatin chemotherapy.
Wilder-Smith OH; Borgeat A; Chappuis P; Fathi M; Forni M
Cancer; 1993 Oct; 72(7):2239-41. PubMed ID: 7690681
[TBL] [Abstract][Full Text] [Related]
18. 5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis.
du Bois A; Vach W; Wechsel U; Holy R; Schaefer W
Br J Cancer; 1996 Oct; 74(7):1137-40. PubMed ID: 8855988
[TBL] [Abstract][Full Text] [Related]
19. Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Hartvig P
J Oncol Pharm Pract; 2007 Mar; 13(1):57-8. PubMed ID: 17621570
[No Abstract] [Full Text] [Related]
20. Reality of the emetogenic level of irinotecan.
Garcia-Del-Barrio MA; Martin-Algarra S; Aldaz Pastor A
Support Care Cancer; 2018 Oct; 26(10):3441-3446. PubMed ID: 29679139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
